Corteva, Inc.: Miss — EPS $0.06, Revenue $1.59B
Earnings MissQ3 2026 · After-market
Did Corteva, Inc. (CTVA) beat earnings today?
No, Corteva, Inc. (CTVA) missed Wall Street analyst expectations for Q3 2026, reporting lower-than-expected EPS and lower-than-expected revenue.
Earnings Per Share-40.00% surprise
$0.06Actual
Expected: $0.10
vs. year ago -57.0%
Total Revenue-10.17% surprise
$1.59BActual
Expected: $1.77B
vs. year ago -9.0%
Released Nov 11 · 4:30 PM ET
Earning Report
| Metric | 3Q 2026 | 3Q 2025 | YoY Change % |
|---|---|---|---|
| Net Sales | $1.59B | $1.74B | -9.0% |
| Revenue detail — reported lines | |||
| └─North America | $574.00M | $537.00M | +7.0% |
| └─EMEA | $239.00M | $213.00M | +12.0% |
| └─Latin America | $570.00M | $791.00M | -28.0% |
| └─Asia Pacific | $208.00M | $201.00M | +3.0% |
| Net Loss | $(54)M | $60.00M | -190.0% |
| GAAP EPS | $(0.08) | - | -189.0% |
| Operating EPS | $0.06 | - | -57.0% |
Financial Outlook / Guidance
| Metric | FY 2026 Outlook |
|---|---|
| Guidance | |
| Adjusted Pro Forma Operating EBITDA | $1.1B-$1.125B |
| Adjusted Pro Forma Operating EPS | $0.76-$0.80 |
FY 2026 Outlook
- Adjusted Pro Forma Operating EBITDA
- Guidance$1.1B-$1.125B
- Adjusted Pro Forma Operating EPS
- Guidance$0.76-$0.80
Business Highlights
- ➤Strong new product sales helped mitigate broader market headwinds.
- ➤North America volume benefited from new product growth and early demand.
- ➤EMEA demand was strong for new and differentiated products.
- ➤Asia Pacific demand for new products supported volume growth.
- ➤Board authorized its first common dividend following the spin.
- ➤Corteva is optimizing its Crop Protection manufacturing and external-partner network.
- ➤Crop Protection restructuring activities are expected to be substantially complete in 2028.
- ➤Corteva’s portfolio includes differentiated chemistries, biologicals and seed-applied technologies.
Management Commentary
Luke Kissam, CEO
“We executed well against the things we can control. New products performed strongly, productivity delivered, and we generated broad-based organic growth outside Latin America. The pressure remains concentrated. Acetochlor pricing in the U.S. was consistent with our expectations, but Brazil was materially weaker than anticipated. While those conditions are reflected in our updated outlook, our strategy has not changed. Innovation, productivity and disciplined execution remain the foundation for sustainable long-term growth.”